Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.7K | $-7.23M | $-13.61 |
| 2024 | $45.7K | $-6.99M | $-7480.22 |
| 2023 | $75.4K | $-4.91M | $-79782.00 |
| 2022 | $60.4K | $-7.07M | $-177396.00 |
| 2021 | $60.3K | $-4.95M | $-120035.00 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-1.05 per share
Typical surprise -6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.12 vs $-1.05miss
- Thu, May 21$-1.34 vs $-1.55beat
- Wed, Feb 25$-3.60 vs $-3.60beat
- Wed, Nov 12$-2.93 vs $-2.64miss
- Thu, Aug 14$-2.75 vs $-2.26miss
- Thu, May 15$-9.32 vs $-1447.20beat
Estimates and results for ACON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ACONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Neutral
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio coveri
View source ↗